Cytokinetics to report ACACIA-HCM trial results for aficamten on May 5

May 4, 2026 4:00 PM

Cytokinetics (NASDAQ: CYTK) will announce topline results from its pivotal Phase 3 clinical trial ACACIA-HCM on May 5, 2026. The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found